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Abstract: 191/150-200 
Primary ciliary dyskinesia (PCD) is a genetically and clinically heterogeneous syndrome. Impaired 
function of motile cilia causes failure of mucociliary clearance.  Patients typically present with 
neonatal respiratory distress of unknown cause, and then continue to have a daily wet cough, 
recurrent chest infections, perennial rhinosinusitis, otitis media with effusion and bronchiectasis. 
Approximately 50% of patients have situs inversus, and male and female infertility is common. 
Whilst understanding of the underlying genetics and disease mechanisms have substantially 
advanced in recent years, there remains a paucity of evidence for treatment.  Next generation 
sequencing has increased the trajectory of gene discovery, and mutations in >40 genes have been 
reported to cause PCD, with many others likely to be discovered. Increased knowledge of cilia genes 
is challenging our perceptions of the clinical phenotype, as some recently reported genes are 
associated with more mild respiratory disease. Developments in genomics and molecular medicine 
are rapidly improving the diagnosis of patients, and a genetic cause can be identified in 
approximately 70% of patients known to have PCD. A number of groups are now investigating novel 
and personalized treatments, although gene therapies are unlikely to be available in the near future.  
Key messages  
• Primary ciliary dyskinesia (PCD) is a syndrome caused by mutations in genes responsible for 
structure and function of motile cilia;although mutations have been identified in more than 
40 responsible genes, the genetic cause of PCD cannot yet be found in ≈25% of patients. .  
• A PCD diagnosis can be confirmed by identification of a hallmark ultrastructural defect by 
transmission electron microscopy or bi-allelic pathogenic mutations in a known PCD gene. 
• Genetic advances are identifying patients with atypical presentations of PCD and have 
confirmed some overlaps with non-motile ciliopathies  
• No diagnostic test is perfect for PCD; therefore, diagnosis relies on a combination of tests 
and no test can be used in isolation. 
• A number of genotype-phenotype associations have been described in small studies, and 
international collaboration and prospective registries are now needed to properly 
understand these.  
• In the absence of disease-specific evidence, respiratory management of PCD is based on 
evidence from cystic fibrosis. PCD guidelines recommend regular airway clearance and 
treatment of pulmonary exacerbations with antibiotics for all patients. Early steps for 
personalised medicine are being taken in light of genetic understanding.    
 
Introduction:   
Primary ciliary dyskinesia (PCD) is a rare syndrome, characterized by extensive genetic heterogeneity 
and clinical variability. Mutations in over forty genes have been reported to cause PCD, and genes 
continue to be discovered. Abnormal ciliary function leads to unexpected neonatal respiratory 
distress in term infants, persistent wet cough from early infancy, bronchiectasis, chronic 
rhinosinusitis, and conductive hearing impairment; 50% of patients have situs inversus, and 
infertility is common 1. Disease progression is highly variable, with some patients maintaining 
reasonably good lung function and quality of life into later adulthood, whilst others have worse 
outcomes2-5. There is increasing evidence that mutations in different genes lead to variable 
phenotypes, for example some genes are never associated with situs anomalies, and variants in 
others are more likely to cause infertility 6,7. There is limited but increasing evidence that some 
genes are associated with severity of pulmonary disease8-11. 
PCD is estimated to affect 1:10-15,000 Europeans, and is more common in populations with closed 
genetic pools12-14; interestingly genetic heterogeneity is seen in socially isolated consanguineous 
populations15,16. Estimates of prevalence are limited outside Europe, but it is expected that PCD is 
more common in certain populations, such as those from Arabic countries 17,18. A survey of European 
PCD specialists reported that only a small percentage of the expected patients have been diagnosed, 
and patients reported through an international survey that 37% had visited a doctor with PCD-
related symptoms more than 40 times before being referred for testing12,19. The reasons for under-
diagnosis are multi-factorial including difficulty accessing diagnostic services and the lack of 
awareness of the syndrome amongst general physicians19. Symptoms are non-specific, and patients 
with situs inversus, which is rare in the general population, are diagnosed earlier than those with 
normal organ positioning12. Clinical tools have been developed to help physicians identify patients 
for testing20,21, but these are based on ‘typical’ symptoms. We are increasingly aware of genotypes 
which are associated with atypical presentations. 
As with other rare diseases, the evidence base for treating patients is lacking. In addition to a 
handful of small PCD studies, consensus guidelines are based on evidence from more common 
disorders such as cystic fibrosis (CF) and chronic rhinosinusitis22,23.  
In this review, we discuss the current state-of-the-art regarding the underlying mechanisms of PCD 
and how this might inform our understanding of clinical presentation and natural disease 
progression. We review current diagnostic and management strategies for patients with PCD. We 
will discuss how the improving knowledge of PCD genetics is impacting our understanding of the 
phenotype, our conduct of diagnostic testing and our management of patients. The authors reflect 
on the expanding phenotype, and how this challenges our definition of PCD.  
 
Search strategy and selection criteria  
This manuscript is not a systematic review but consists of the authors’ expert knowledge of the 
disease area informed by the literature; we searched PubMed, for evidence relating to PCD in the 
English language since 2000: using the search term “primary ciliary dyskinesia” in combination with 
the following: (diagnosis; clinical symptoms/clinical presentation/phenotype; treatment/clinical 
trial). After identifying eligible studies, we checked for additional citations in their reference lists. 
Clinical features  
Patients with PCD usually present with a classic clinical phenotype1,20,21,24.  Defining and 
understanding these manifestations allows for earlier recognition and identification of these 
patients.  In PCD, over eighty percent of the population will present with respiratory distress at birth 
despite being term.  This distress typically occurs 12 to 24 hours after birth and many infants require 
prolonged oxygen due to hypoxemia25.  Furthermore, chest radiographs in infants with PCD often 
reveal lobar collapse.   
Impaired mucociliary clearance in this population leads to chronic wet cough associated with 
rhinorrhea.  These manifestations occur daily and typically begin during the first months of life.  The 
majority of patients with PCD have recurrent acute otitis media, otitis media with effusion, and 
chronic otitis media1,26,27. Repeat ear infections may lead to transient or permanent hearing loss, the 
latter causing significant morbidity later in life.  Sinusitis is a common manifestation in this 
population, but may not be detected in younger patients due to lack of imaging8,23.  
Recurrent pulmonary infections due to impaired mucociliary clearance ultimately leads to 
bronchiectasis.  Respiratory cultures (sputum, bronchoalveolar lavage) in the younger population 
often reveal Streptococcus pneumonia, Moraxella catarrhalis, Staphylococcus aureus and 
Hemophilus influenzae.  Pseudomonas aeruginosa may be detected in children with PCD, but 
becomes more predominant in adults8,28-30.   Chest computed tomography imaging during infancy 
have revealed early airway manifestations, including bronchiectasis31.  Infertility is often present in 
males.  In females, fertility may be difficult due to impaired cilia motion in the fallopian tubes7,24. 
Situs inversus occurs in fifty percent of PCD patients; and situs ambiguus, including heterotaxy, has 
been reported in up to 12% of patients with PCD6,32,33.  These patients have an increased incidence of 
congenital heart disease. Children and adults with situs inversus and/or heterotaxy associated with 
respiratory manifestations should be evaluated for PCD23,34.   
Diagnosing PCD has historically been difficult due to the need for specialized testing coupled with 
lack of general awareness leading to the failure of clinicians to recognize the classic phenotype.  
Recently, four clinical features were defined as predictive of PCD, including laterality defect; 
unexplained neonatal respiratory distress; early-onset, year-round nasal congestion and wet cough.  
The sensitivity and specificity of having PCD if all four features were present was reported at 0.21 
and 0.99, respectively21.  In another study, a scoring tool, PICADAR (Primary Ciliary Dyskinesia Rule) 
was developed to predict the diagnosis of PCD in a symptomatic population20. The seven features in 
addition to persistent wet cough that were predictive of PCD included full-term gestation, neonatal 
chest symptoms, admission to the neonatal intensive care unit, chronic rhinitis, ear symptoms, situs 
inversus and congenital cardiac defect.  PICADAR represents a diagnostic algorithm that may prove 
useful when delineating whether a work-up is indicated for PCD (score of 4: sensitivity 0.97, 
specificity 0.48; score of 5: sensitivity 0.90, specificity 0.75 20.  However, these predictive diagnostic 
tools may be under-utilized if general awareness remains low. Efforts to raise knowledge, led by 
specialists in the field, is already improving referrals. In the UK, the age of diagnosis in the pediatric 
population has dropped from 4.8 years (2009)12 to 2.6 years (2015- unpublished data). In North 
America, there are now 41 accredited PCD Foundation centers; this initiative is increasing the 
identification and recognition of this rare disease. Further research is warranted in high risk 
populations to investigate whether predictive tools with targeted nasal nitric oxide testing could 
further promote early referral. Adult bronchiectasis clinics are a likely reservoir of undiagnosed 
patients, and work is needed to raise awareness amongst adult pulmonologists. Modified predictive 
tools will be needed for this population since many adults are unlikely to recall early life events 
which are captured by the current questionnaires20,21. For example a modified PICADAR score and 
low nasal nitric oxide was accurate in identifying PCD amongst adults with bronchiectasis35.  
Significant heterogeneity exists within the PCD population in age-matched lung function values2,3,8. 
In some cases, genotype accounts for the variability between patients, for example mutations in 
CCDC39 and CCDC40 are associated with worse lung function, whilst DNAH9 mutations are 
associated with milder disease8-10. In a recent publication, the rate of FEV1 decline was highly 
variable in 137 patients with PCD followed at seven centers for five years9.  Furthermore, ventilation 
inhomogeneity as measured through the multiple breath washout technique may be abnormal even 
with normal spirometric values36,37.   
Diagnosis  
Multiple investigations are usually required to make a diagnosis of PCD. There are two evidence 
based diagnostic guidelines published by the European Respiratory Society (ERS) and the American 
Thoracic Society (ATS) respectively34,38. Both guidelines recognise that there is no perfect diagnostic 
test for PCD. There is a lack of sensitivity or specificity for most tests used, specialist equipment and 
expertise is required and consequently access to testing can be problematic. Guidelines recommend 
a combinations of the following tests:  
Nasal Nitric Oxide (NO)   
The level of NO gas in the nasal cavity can be measured with a gas analyser. This test is ordinarily 
reserved for children who have developed paranasal sinuses and are able to comply with velum 
closure manoeuvres (usually >4yrs old). Most individuals with PCD have NO values which are tenfold 
lower than healthy controls39. Sensitivity and specificity are good (98% and >99.9%, respectively) at a 
cut off at 77nl/min when measured in patients with symptoms of PCD, with a chemiluminescent 
analyser, using ATS/ERS NO measurement guidelines40. However there can be several other causes 
of reduced nasal NO such as smoking or nasal obstruction. Patients with cystic fibrosis are also 
reported to have reduced NO values41,42. Conversely, although a normal nasal NO level remains 
helpful to exclude a diagnosis, there are exceptions where nasal NO is above the typical cut-off used 
for diagnosing PCD. These include individuals with mutations in GAS8, STK36, CCDC103, RSPH1 and 
GAS2L211,43-46. Increasing knowledge of genetics has highlighted that nNO cannot be used in isolation 
as a screening test, as certain patients with PCD will be missed. 
New portable analysers make NO testing increasingly accessible in the clinic, although both 
sensitivity and specificity when using these analysers is reduced47.  
High speed video microscopy analysis (HSVMA) 
Live samples, usually obtained by nasal brushing, can be assessed for ciliary beat frequency and 
pattern. This functional assessment is achieved ex-vivo using a light microscope fitted with a high 
speed video camera. Ordinarily cilia beat in a metachronal wave with an effective forward stroke 
followed by a recovery stroke. Specific beat patterns are observed in patients with PCD: completely 
immotile, immotile with occasional residual movement, reduced bend and reduced beat amplitude, 
hyperfrequent with reduced beat amplitude or with a circular motion when viewed from above. In 
some cases a mixed phenotype can occur.  Correlations between cilia beat pattern and 
ultrastructural defect or genotype in PCD have been demonstrated48,49. Ciliary beat frequency is less 
accurate when used in isolation and is dependent on several factors, such as patient age, 
formulation of the maintenance media and sample temperature50. Recent evidence shows excellent 
accuracy of HSVMA for diagnosis, however the limitation is the specialist equipment required to 
record the videos and the expertise required to interpret the beat pattern. Also pathogenic variants 
in some genes can be associated with fairly normal ciliary beating (e.g. RSPH1, CCDC103, DNAH9) 
Immunofluorescence:  
Antibodies directed against ciliary proteins are becoming increasingly available and are used 
regularly in a research setting to confirm absence of ciliary protein and the pathogenicity of a 
genetic mutation51. Recent evidence for the use of antibody testing with a panel of six antibodies 
shows similar sensitivity and specificity as TEM in clinical practice52.  
Transmission electron microscopy:  
Normal ciliary ultrastructure consists of a “9+2” structure: 9 peripheral microtubule doublets, 
surround the central pair of single microtubules (Figure 1). Each doublet is connected with the 
central pair by radial spokes, and neighbouring doublets are joined by the nexin dynein regulatory 
complex (N-DRC). The outer microtubular doublets contain regularly repeating structures known as 
outer and inner dynein arms (ODA and IDA), which are responsible for the generation of ciliary 
motion through ATPase activity.  
Since the first description of the condition by Afzelius, PCD diagnosis has relied on ultrastructural 
analysis by TEM53. TEM remains a robust test to confirm a diagnosis although increasingly cases with 
normal ultrastructure have been identified 50,54,55. Despite poor sensitivity, the specificity of TEM for 
diagnosis of PCD is excellent34. As noted above, normal ciliary ultrastructure may occur in those with 
PCD. Hallmark diagnostic defects for PCD include: absence of the ODA, absence of the ODA and IDA, 
and absence of the IDA with microtubular disorganisation. In addition ultrastructural defects which 
can support a diagnosis when used in combination with other tests have been identified. These 
include central complex defects, mislocalisation of basal bodies, isolated microtubular 
disorganisation and partial defects of the outer +/- inner dynein arms affecting <50% of cross 
sections. Figure 2 shows examples of the various ciliary ultrastructural changes according to PCD 
genotype. 
 
Genotyping  
Both ERS and ATS guidelines agree that a bi-allelic pathogenic mutation or hemizygous X-linked 
mutation in a known PCD gene confirm a diagnosis34,38.  Around 65-70% of PCD cases diagnosed by 
other methods can be genetically solved. However many individuals have variants of unknown 
significance or mono-allelic heterozygous variants which require confirmation by functional and 
structural tests (HSVMA, IF and TEM). It is not unusual to identify one or several rare missense 
variants that are not linked to the disease, due to the large size and number of genes sequenced in 
PCD patients; therefore there is significant risk of false positive results unless the genetic diagnoses 
are supported by corresponding HSVMA or TEM results (Table 1). Since genetic testing fails to 
identify ≈30% of patients, it cannot exclude a diagnosis. nNO with hallmark TEM or repeatedly 
abnormal HSVMA can probably identify most patients with PCD associated with normal genetics to 
ensure they receive appropriate clinical care.  
Summary 
We emphasise the risks of relying on any one test to diagnose PCD, and the benefit of using a 
combination of tests50. No test is perfect, and it is only by comparing results from various tests that 
the clinician can be confident. Importantly, all diagnostic tests should be conducted an interpreted 
by PCD experts who understand the relative risks of false positive and negative results for the 
individual tests. Due to imperfect testing by all modalities it is likely that some patients with PCD are 
not recognised despite adherence to ATS or ERS guidelines. Therefore research and development in 
PCD gene discovery and improved diagnostic techniques are crucial. Novel approaches such as 
radiolabelled mucociliary clearance provide additional data which may help exclude a diagnosis of 
PCD when this functional test is normal in difficult diagnostic cases 56,57. In addition new advances in 
electron microscopy such as 3D electron tomography provide insight into PCD cases previously 
thought to have normal ultrastructure 58.  
 
Genetics and disease mechanisms  
Mutations of more than 40 different genes have been reported that cause PCD (Figure 1). Most PCD 
variants are transmitted in an autosomal recessive fashion. However, X chromosomal recessive 
inheritance has also been reported for a few genes59,60. Motility of respiratory cilia is generated and 
regulated by complex mechanisms involving several large multimeric protein complexes. Mutations 
affecting many of these proteins can result in PCD. In approximately 50% of cases, mutations in 
some genes are associated with laterality defects, whilst mutations in other genes are always 
associated with situs solitus. Dyskinesia of the cilia severely impairs mucocilary clearance, leading to 
recurrent and chronic airway infection and inflammation.  IL-8, neutrophils, and neutrophil elastase 
activity are significantly elevated in the PCD airway, contributing to the inflammatory 
environment61,62. Furthermore, peripheral blood monocytes from PCD patients produce higher levels 
of inflammatory cytokines when stimulated compared to those from healthy individuals, perhaps 
contributing to the chronic airway inflammation and resulting tissue damage from infections 63. This 
recurrence and persistence of airway infections and inflammation contribute to progressive lung 
disease and eventually bronchiectasis. 
PCD associated with laterality defects 
PCD individuals with abnormal outer dynein arm (ODA) composure, abnormal ODA docking 
machinery, abnormal cytoplasmic dynein preassembly or tubular disorganization share the 
possibility during embryogenesis of randomization of left-right asymmetry. Thus, half of all affected 
individuals exhibit situs inversus or heterotaxy, because those disease mechanisms also affect nodal 
cilia function important for determination of left-right asymmetry during early embryogenesis. The 
association of situs inversus with PCD is also referred to as Kartagener syndrome.  
Defects of outer dynein arm composure:  The ODA, attached to the outer doublets, generate the 
main mechanical force to produce cilia bending. Genetic defects in genes that encode ODA 
components such as the heavy chains DNAH5, DNAH1164,65, the intermediate chains DNAI1 and 
DNAI266,67 as well as light chains such as DNAL1 and NME868,69 all result in dysfunction of ODAs.  
Mutations in the gene DNAH5 result in the most frequent defect reported in PCD individuals.  High-
speed video microscopy analyses (HSVMA) of cilia beating reveals immotile cilia; transmission 
electron microscopy (TEM) and immunofluorescence microscopy analysis (IF) confirm deficient/ 
absent ODAs. 
Mutations in genes encoding intermediate chains of the ODAs such as DNAI1 and DNAI2, or 
encoding the light chain DNAL1 cause similar defects to DNAH5 mutations that can be recognized by 
TEM, IF and HSVMA. Interestingly, mutations in the NME8 gene have been reported to result in a 
variable phenotype of the ultrastructure69. Approximately half of the cross sections showed ODA 
defects, the other half showed normal composure. In the original reports it had been suggested that 
some cilia might lack ODAs and that other cilia might assemble ODAs. However, recently it has been 
discovered that two distinct ODA populations are present in respiratory cilia along the ciliary lengths.  
ODA complexes type 1 containing the beta-heavy chain DNAH11 are located in the proximal 
compartment whereas ODA complexes type 2 containing the beta-heavy chain DNAH9 are located in 
the distal compartment10,51,70. Thus, it is more likely that in NME8 mutant cilia the distal ciliary 
axonemes lack ODAs type 2.   
DNAH11 mutations cause a distinct PCD phenotype characterized by a hyperkinetic beating pattern 
with reduced beating amplitude. The bending of the proximal ciliary compartment is deficient in 
DNAH11 mutant cilia. DNAH11 mutations do not cause obvious ultrastructural defects readily 
identifiable by TEM55. Therefore, DNAH11 mutations are often overlooked in centres that rely only 
on TEM to establish PCD diagnosis. Immunofluorecence microscopy with anti DNAH11 antibodies 
can detect some PCD individuals with mutations in DNAH1171. Recently mutations in DNAH9 have 
been reported in PCD individuals with mild or no respiratory disease70. DNAH9 mutant cilia lack 
ODAs of the distal ciliary axonemes and exhibit only subtle beating abnormalities10,70. 
Immunofluorescence microscopy analysis utilizing antibodies directed against ODA components 
DNAH9, DNAH11, DNAH5, DNAI1 or DNAI2 can easily depict the distinct defects of ODA composure 
in the different genetic PCD variants. 
Defects in outer dynein arm docking and targeting: ODAs are attached to the outer doublets by 
complicated mechanisms involving a multimeric docking machinery which are referred to as ODA 
docking complexes (ODA-DCs). Mutations in genes encoding different ODA-DC components such as 
CCDC11414,72, ARMC473, CCDC15174,75 and TTC25 76 can result in abnormal ODA docking. Thus, 
mutations of these genes result in absence of ODAs from the ciliary axonemes, usually easy to detect 
by TEM and IF. HSVMA readily identifies predominantly static cilia. In addition, with the use of 
antibodies targeting the ODA docking machinery it is possible to distinguish molecular defects 
caused by abnormal ODA composure or by abnormal ODA docking. Interestingly, the ODA-DC 
protein TTC25 appears to be the major component of the ODA docking machinery because in those 
mutant cells, ODA-DCs such as CCDC114, CCDC151 and ARMC4 cannot be assembled. In contrast, 
ARMC4 mutations cause abnormal ODA docking that is more prominent in the distal ciliary axoneme 
than proximally resulting in a heterogeneous picture along the axoneme. CCDC103 43,77 is not a 
classical ODA-DC protein but is involved in ODA targeting. LRRC56 mutations disrupt intra-flagella 
transport-dependent delivery of ODA components and result in subtle defects of distal ODAs78.  
Defects in cytoplasmic preassembly of dynein arms:  ODAs as well as inner dynein arms (IDAs) 
which are important for the regulation of the ciliary beating are preassembled in the cytoplasm prior 
to delivery to their final docking sites at the outer doublets along the ciliary axoneme. Therefore, 
mutations in genes that alter cytoplasmic preassembly processes result in defects of ODAs as well as 
IDAs. Those preassembly factors are referred to as dynein axonemal assembly factors (DNAAFs). 
Mutations in genes that encode these cytoplasmic preassembly factors  such as DNAAF1 79,80, 
DNAAF281, DNAAF3 82, DNAAF4(DYX1C1)83, DNAAF5 (HEATR2)84, LRRC6 85, ZMYND10 86,87, SPAG1 88, 
C21ORF59 89, DNAAF6 (PIH1D3) 59,60 and CFAP300 (C11ORF70)90 cause PCD with combined ODA and 
IDA defects. Because the cilia lack outer as well as IDAs, most mutations result in complete cilia 
immotility, easily identified by HSVMA. For DNAAF2 as well as for hypomorphic mutations in 
DNAAF4, some residual cilia motility can be retained due to partial assembly of outer and IDAs. The 
defects are usually more pronounced in the distal ciliary axoneme than proximally.  
In male individuals carrying mutations in genes encoding cytoplasmic preassembly factors, sperm 
dysmotility indicates that the molecular disease mechanisms of cytoplasmic preassembly also plays a 
role in sperm flagella.  
Defects of the ninety six nanometer ruler machinery: The ninety six nanometer ruler proteins 
CCDC39 91 and CCDC40 92 are responsible for the correct establishment of the 96 nm repeats along 
the ciliary axoneme. In each 96 nm axonemal repetitive unit four ODAs and various distinct IDAs are 
attached to the outer doublets.  Those ruler proteins are also important for anchoring the dynein 
regulatory complex (nexin links) connecting the outer doublets as well as IDA proteins such as 
DNALI1 to the axoneme. The cilia beat with a reduced bend and amplitude. The ultrastructural 
defects seen by TEM comprises a severe tubular disorganization as well as deficiency of IDA 
components; the ODA composure is not affected. In all reported cases, recessive mutations in the 
genes CCDC39 or CCDC40 have been identified. With the use of IF it has been confirmed that mutant 
cilia lack nexin link proteins such as CCDC164 93, CCDC65 89, GAS845,94 or LRRC48. In addition, patients 
lack IDA proteins like DNALI1 in the axonemes. Thus, HSVMA, TEM and IF can easily identify patients 
with defects in the genes CCDC39 or CCDC40.  
PCD without laterality defects 
Several disease mechanisms can alter cilia motility of multiciliated respiratory cells whilst not 
affecting function of nodal monocilia during early embryogenesis. Those genetic defects are not 
easily diagnosed by TEM and they can benefit from analysis by IF. 
Defects in radial spoke components: Mutations in the genes encoding radial spoke proteins RSPH1 
95, RSPH4A 96, RSPH9 96, RSPH3 97 and DNAJB13 98 cause abnormal radial spoke composure. However, 
this abnormal radial spoke composure causes only subtle ciliary beating abnormalities, usually 
comprising of rotational or stiff beating patterns. IF shows abnormal composure by demonstrating 
absence of radial spoke head proteins99.  
Defects in central pair associated proteins : Genetic defects encoding central pair associated 
proteins such as HYDIN 100 and STK36 46 have been reported. Those genetic defects are not 
associated with obvious ultrastructural abnormalities. In some cross sections occasionally central 
pair abnormalities can be noted by TEM. However, those abnormalities can also occur in normal 
individuals and they are not pathognomonic. Genetic testing for HYDIN mutations is complicated. 
Due to a recent evolutionary event, HYDIN became duplicated and therefore most of the coding 
exons of HYDIN are also present in the pseudogene HYDIN2. Due to this duplication DNA sequence 
analysis of HYDIN is not easily established. Therefore, some commercial genetic kits do not screen 
for HYDIN mutations or report a reduced sensitivity for this genetic testing. Diagnosis of central pair 
defects is also hampered by the fact that some individuals show normal nasal NO production rate 
and the ciliary abnormalities detected by HSVMA are subtle. Elucidating these PCD genotypes 
highlights potential cases which risk being missed by standard functional tests. 
Isolated nexin link defects: Genetic defects encoding the so-called nexin link dynein regulator 
complex proteins (N-DRCs) result in abnormalities of the nexin link structure connecting the outer 
doublets. So far, mutations in the genes CCDC164 93, CCDC65 89, and GAS8 45 have been reported. 
TEM shows no discernible abnormalities. Occasionally, outer doublets are not well aligned in the 
periphery of the cross section. However, those abnormalities can be also observed in normal 
individuals.  The ciliary beat pattern of patients with isolated nexin link defects is occasionally stiff, 
but can also appear normal. IF identifying N-DRC defects using antibodies targeting N-DRC proteins 
such as GAS8 are widely used. 
Reduced generation of multiple motile cilia: These individuals show a reduced capacity to generate 
multiple motile cilia. In patients with mutations in MCIDAS 101respiratory cells usually lack any motile 
cilia or show only very few motile cilia. MCIDAS appears to be a major regulator of ciliogenesis in 
multiciliated cells. Downstream of MCIDAS, CCNO 102 is responsible for the function in the 
deuterosome dependent amplification of basal bodies and basal body docking. Therefore, mutations 
in CCNO result in a defect with a very low number of cilia covering the airway cells. Residual cilia can 
still show normal cilia motility. TEM can also demonstrate mislocalised basal bodies in the 
cytoplasm. Because the genetic defects solely alter ciliogenesis in multiciliated cells, the function of 
nodal monocilia is not altered. 
Motile ciliopathies with subtle or no respiratory disease: Recently, genetic defects have been 
recognized in individuals with motile ciliopathies that result in randomization of left/right body 
asymmetry and/or male infertility but to date seem to  not suffer from the severe chronic 
destructive airway disease usually reported in PCD.   MNS1 90, DNAH9 10,70 CCDC11 103 and ENCUR 104 
98 belong to this group.   
 
Genotype-phenotype relationships  
Delineation of genotype-phenotype relationships have recently been described in the PCD 
population.  Patients with absent IDA with microtubular disorganisation who have a CCDC39 or 
CCDC40 mutation,  have lower body mass indices and worse lung function that declines more rapidly 
compared to the PCD population with ODA defects and those whom have a DNAH5 mutation, 
respectively9.  Interestingly, patients with microtubular disorganization with IDA defects, many with 
the CCDC39 or CCDC40 mutation, are diagnosed earlier with PCD and even as infants have more 
airflow limitation compared to those with ODA defects8.  Patients with the CCNO and MCIDAS 
mutations have also been reported to have a worse phenotype with significant bronchiectasis, as 
well as increased incidence of hydrocephalus105. It seems reasonable to recommend increased 
surveillance and more aggressive treatment plans for these groups. Conversely those with RSPH1 
mutations appear to have less lung function impairment, a later onset of wet cough, a lower 
prevalence of neonatal respiratory distress and nasal nitric oxide values often outside the diagnostic 
range11. Furthermore, recent data has suggested that mutations in DNAH9 are associated with 
milder respiratory phenotypes6,10 With the increase in discovery of PCD-causing genes, more 
genotype-phenotype relationships will be elucidated. However, caution is needed when interpreting 
genotype-phenotype data based on small numbers of patients with variations in any one gene. 
Moreover, we are aware from diseases such as CF that the phenotype can vary depending on the 
type of mutation within a gene, and how it effects the protein product.  Similar variability is likely 
within PCD genes. 
By definition, patients with PCD have dyskinetic cilia, and our clinical understanding has expected 
airway cilia to be impacted, as confirmed by HSVMA. Recently described mutations in ENKUR and 
CCDC11 impact left-right patterning but do not appear to cause pulmonary disease103,104.  These 
findings are supported by normal ciliary motility seen by HSVMA and normal TEM in patients with 
ENKUR mutations. Given this, some have questioned whether these patients should be included 
within the syndrome of PCD due to the significantly different phenotype that does not benefit from 
the usual PCD management.  Conversely, patients with mutations in CCNO and MCIDAS have 
reduced generation of motile cilia, rather than dyskinesia 101,102. These patients have a severe 
respiratory phenotype and a higher risk of hydrocephalus. However, despite not having dyskinetic 
cilia, they are best managed in specialist PCD clinics.   
Syndromes associated with PCD 
Advances in imaging and genotyping have revealed PCD like features in some patients with non-
motile ciliopathies. Non-motile primary cilia have a role in cell signalling and sensing of the 
extracellular environment. Symptoms among ciliopathies include polycystic kidneys, skeletal 
abnormalities, developmental delay and retinal degeneration. Increasingly abnormalities in motile 
cilia are described in several non-motile ciliopathies including Jeune syndrome 106, nephronophthisis 
type 2 (NPHP2) 107, Leber Congenital Amaurosis (LCA)108 and  Bardet Biedl syndrome109.  
Some males with X-linked mutations in RPGR, which can cause retinitis pigmentosa are also reported 
to have PCD symptoms110 associated with dyskinetic ciliary beating111. OFD1 is an X-linked gene 
associated with several overlapping ciliopathies including oral-facial-digital syndrome and Joubert 
syndrome. When there is also a motile cilia defect the condition is termed Simpson–Golabi–Behmel 
syndrome. These individuals suffer from PCD symptoms, overgrowth and can also have abnormally 
large kidneys, liver and spleen112.  
Management  
Since there is no cure for PCD, the aim of treatment is to delay the decline in pulmonary airways 
disease, whilst maintaining patients’ health, social and psychological wellbeing. The variability in 
clinical manifestations and the scarcity of data from clinical trials make it difficult to formulate a 
standardised management plan that is suitable for all patients. Management is often extrapolated 
from other diseases such as CF and chronic rhinosinusitis. Although both CF and PCD inevitably lead 
to bronchiectasis, their underlying patho-mechanisms and clinical course are different113 2,114,115 . 
Response to treatment is likely to vary in PCD and international collaborations are urgently needed 
to ensure a sufficient number of eligible patients for well-designed treatment trials.  
General physicians usually have a poor knowledge of managing rare diseases. Guidelines therefore 
recommend that patients should be seen several times a year in PCD centres by a specialist 
multidisciplinary team22,23,116.  
General Health 
There is growing evidence for the importance of growth and nutrition in children with PCD. The 
International PCD Cohort (iPCD) have reported impaired height from an early age, and a longitudinal 
study has shown reduced growth throughout childhood resulting in loss of body height by 
adulthood117,118. Several studies have observed a relationship between lower nutritional status and 
worse lung function2,117,119, although other studies have found no association115,120. Furthermore PCD 
patients have low levels of vitamin D, a finding associated with disease severity in 
bronchiectasis119,121. Knowledge of genotype might indicate the patients at increased risk; e.g. 
patients with mutations in CCDC39 and CCDC40 have been observed to have diminished growth 
parameters in comparison to DNAH59. 
Patients with PCD often have poor aerobic fitness and regular exercise should be encouraged to 
improve general wellbeing and perhaps assist in mucus clearance122,123.  
Pulmonary Management 
There is recent evidence that patients with PCD have more impaired lung function than those with 
cystic fibrosis (CF) from early childhood2. With the paucity of evidence, treatment is based on more 
common diseases, in particular CF116. Guidelines recommend monitoring to include culture of 
sputum or cough swabs every 3 to 6 months22,23,116. Spirometry is routinely used, but is not as 
sensitive as lung clearance index (LCI) measured by multiple-breath washout for detecting 
disease36,124-127. LCI is easier to measure than spirometry in young children, but information 
regarding the relationship between FEV1 and LCI in PCD is conflicting124-126. Multiple-breath washout 
equipment is not always available and testing can be time consuming. LCI is not able to distinguish 
between individuals with reversible and irreversible structural damage36; therefore lung imaging is 
needed to characterise structural changes. Chest X-rays are probably the most commonly used 
imaging in clinical practice for assessing structural lung changes in PCD22,23. Most infants with PCD 
have unexpected neonatal respiratory distress despite term birth. The majority of these infants have 
evidence of lobar collapse, usually involving the upper lobes25. However, chest x-rays are not 
sensitive as a monitoring tool to detect early pulmonary changes. Due to concern over the radiation 
exposure HRCT is not recommended for routine annual monitoring, but can be used intermittently 
or when clinically indicated. Typical changes seen in PCD include bronchiectasis, peribronchial 
thickening, mucus plugging, atelectasis and consolidation or collapse. Lung disease, in particular 
bronchiectasis, predominantly occurs in the middle and lower lobes, with relative sparing of the 
upper lobes115,128-129. As expected, structural changes increase with age and are associated with lung 
function128,129. There are no scoring systems specific for PCD. Studies have therefore used the scoring 
systems derived for CF lung disease, (i.e. Brody and Bhalla) 130,131. However, the structural lung 
disease in CF and PCD differ, and PCD-specific scoring systems are needed to fully capture changes 
132 114. 
To avoid the radiation doses associated with HRCT imaging, there is a growing interest in magnetic 
resonance imaging (MRI) to assess structural and functional changes37,133,134. Further developments 
of lung MRI may allow longitudinal assessments over time in PCD as well as provide the ability to 
quantify structural changes on a more regular basis and serve as endpoints in short term 
intervention therapy trials.Whilst there is virtually no evidence, experts agree that a cornerstone of 
treatment is airways clearance with the aim of preventing infections, atelectasis, bronchiectasis and 
respiratory failure 22,23,116. Techniques include a combination of breathing manoeuvres, positioning, 
manual percussion, with adjuncts including ‘vest therapy’ (high frequency chest wall oscillation), PEP 
devices and oscillatory-PEP. Current practice individualises the method based on disease severity, 
patient age and preference135, with clearance usually recommended at least twice daily22,23,116. If 
patients have difficulty clearing secretions, nebulised treatments might augment mucus clearance, 
although evidence is poor in PCD. The only clinical trial using hypertonic saline failed to show a 
significant effect in comparison to isotonic saline; the study was probably underpowered and the 
outcome measure might not have been ideal, demonstrating the need for multinational trials using 
sensitive outcome measures136. Whilst a small number of case studies have suggested a benefit 
when using recombinant DNase in patients with PCD137-139,  a large trial of patients with non-CF 
bronchiectasis reported more frequent pulmonary exacerbations and an increased decline in 
FEV1140,141. Therefore use of rhDNase in PCD should only be considered on a case-by-case basis.  
Prevention and treatment of pulmonary exacerbations is the second facet of pulmonary care, and 
again evidence is extrapolated from CF142. Prevention includes immunization (influenza, 
pneumococcus etc.), segregation and surveillance programmes. Common isolates include 
Haemophilus influenza, Morexella catarrhalis, Steptococcus pneumoniae and Pseudomonas 
aeruginosa8,29,30,120,143. Although treatment of symptomatic infection is intuitive, the treatment of 
asymptomatic infection is more contentious. In the absence of disease-specific evidence, it is 
generally accepted that treatment should follow CF guidelines, with modification from the high 
doses used in CF. Given the toxic effects of some of these antibiotics, adverse events should be 
monitored in PCD patients.   In the absence of strong evidence, a sensible approach is to treat first 
isolates of pathogens with at least two weeks of antibiotics in an attempt to eradicate. For P 
aeruginosa inhaled antibiotics are usually prescribed; some clinicians will also prescribe an oral 
antibiotic. Patients who do not respond to treatment may require intravenous therapy. Whilst 
prophylactic use of azithromycin can be beneficial in CF and non-CF bronchiectasis, the evidence for 
use in PCD is awaiting results from a recent trial144. 
The role of thoracic surgery in PCD is unclear, but in the authors experience is rarely indicated. Lung 
transplantation is an option in patients with end stage disease, and has been performed in a number 
of patients in the US28. Recent studies indicate that transplantation is undertaken exceptionally 
rarely in Eurpope26,145. Transplantation requires careful planning particularly in patients with situs 
abnormalities. 
Upper airways and ears 
Since the majority of patients with PCD have chronic rhino-sinusitis, otitis media with effusion, and 
chronic otitis media1,26,27, an otolaryngologist should be part of the PCD multidisciplinary team.  
Perennial nasal discharge often starts from early infancy, and can be debilitating, affecting quality of 
life4,5,146. Anecdotally, sino-nasal rinsing with saline can relieve symptoms.  Topical nasal steroids are 
often used although there is no evidence of efficacy147.  
Management of the ears aims to improve hearing and prevent irreversible damage of the tympanic 
membranes. Ear disease is very common, particularly in young children. Symptoms often improve 
with age, although some adults continue to require hearing aids27,148,149.  The conductive hearing loss 
associated with middle ear effusions can delay speech acquisition, impair learning, and create social 
isolation. Hearing should therefore be monitored regularly using age-appropriate methods. Oral 
antibiotic treatment of acute otitis media may prevent complications, and topical antibiotics can be 
prescribed for ear discharge. In PCD, the use of ventilation tubes is controversial because 
troublesome mucopurulent discharge is reportedly more common than in the general population 
(30% versus 5%), however, randomised studies have not been undertaken149,150. The ERS guidelines 
recommend hearing aids rather than ventilation tubes, until such time as the hearing loss resolves22. 
Patients with mutations associated with central complex defects (Table 1), have been reported in 
one study to have more ear-related problems. This group might benefit from more regular 
monitoring149. 
Cardiac disease 
Echocardiogram and abdominal ultrasounds should follow diagnosis in patients with genes known to 
effect laterality (Table 1).  
Fertility 
Infertility is common in PCD and patients need access to specialist care for assisted fertility7. There is 
increasing data to guide which patients require counselling regarding fertility, for example, patients 
with mutations in CCDC114 appear to have normal fertility14, whilst limited data suggests male 
infertility is highly likely in patients with mutations in CCDC39, CCDC40, DNAAF1 and LRRC67. A 
number of men have successfully fathered children following intracytoplasmic sperm injection (ICSI).  
Information regarding pregnancy is limited, but anecdotally, a number of women with PCD have 
successfully delivered healthy babies. There is dogma that women are at high risk of ectopic 
pregnancy, but experience of the authors as well as lack of epidemiological evidence cast doubt on 
this7.  
Potential novel therapies 
There is much interest in genetic correction of mutated PCD genes as a potential cure.  Several 
studies have reported partial recovery of ciliary beating investigated using lentiviral transfection or 
TALENs (transcription activator-like effector endonucleases) in ciliated cell culture models and 
transgenic mouse models151-153. Other gene editing techniques exist, for example read through 
therapies154 and CRISPR-Cas9. With recent successes in cystic fibrosis, and the increased 
understanding of the genetic basis of PCD, there are a number of researchers investigating targeted 
small molecule therapies.  
Summary  
In summary, PCD is a syndrome caused by genetic mutations effecting motile cilia, causing disease of 
the upper and lower airways. Next generation sequencing has led to advances in the discovery of 
new PCD genes over the past decade, and over 40 genes are now reported to cause this rare disease. 
This remarkable progress is impacting diagnostic capabilities, genetic counselling and has the 
potential to lead to new therapeutic options and personalised care.  
There is increasing understanding of the influence of genotype on clinical presentation, although 
research is limited by the number of patients with mutations in any one gene. There is no gold 
standard diagnostic test, and a combination of nNO screening, analysis of cilia ultrastructure by EM; 
analysis of ciliary function by HSVM, Immuno-labelling of ciliary proteins (IF) and genetic testing can 
be used.  Because there are a large number of implicated genes and mutations, and because many 
genes have yet to be found, genetic testing is not yet a definitive diagnostic test for PCD. There is no 
cure for PCD and management focuses on careful monitoring and physiotherapy as well as 
treatment of infections. The lack of a definitive diagnostic test and absence of specific treatments 
highlight the importance of collaborative international research for this rare disease. 
Discussions between patient representatives and clinicians are needed to clarify the definition of 
PCD in this genomic age. Whilst previously we presumed that all patients would have pulmonary 
involvement, there have been recent discoveries of genes (e.g.ENKUR) affecting motile cilia that 
cause situs inversus in the absence of significant chest disease. Should these patients be included in 
the syndrome? Further study is also indicated in patients with mutations in genes where there is 
ciliary dyskinesia, but some mucociliary clearance is maintained (e.g. DNAH9). Conversely patients 
with mutations in CCNO and MCIDAS, do not have dyskinetic cilia. Rather, their relatively severe 
respiratory phenotype, caused by reduced numbers of motile cilia, is typical of PCD. Should this 
group of patients have a different label for their disease, or is it clinically sensible for them to be 
identified as having PCD? There is large heterogeneity and we are at the tip of the iceberg in 
understanding the disease.  
 
  
Table1. Genetic defects in PCD, and the associated phenotypes where these differ from ‘classical’ PCD 
Functional 
defect 
Gene OMIM 
Predominant 
ultrastructural 
defect by  TEM 
Predomina
nt  
HSVMA 
      Phenotype notes Ref. 
Randomization of L/R asymmetry 
ODA DNAH5 603335 ODA Static   64 
 DNAH11* 603339 Normal$ 
Hyperfrequent/ stiff 
at base 
 65 
 DNAI1 604366 ODA Static  66 
 DNAI2 605483 ODA Static  67 
 DNAL1 610062 ODA Static  68 
 NME8 607421 ODA Static  69 
 DNAH9 603330 ODA-type 1 Normal/ stiff at top 
Normal NO/ milder resp. 
phenotype 
10,70 
ODA CCDC114 615038 ODA Static Preserved fertility 14,72 
Docking ARMC4 615408 ODA Static  73 
 CCDC151 615956 ODA Static  75 
 CCDC103 614677 ODA/ normal$$ Static/ normal2 
Normal NO/ milder resp. 
phenotype$$ 
77 
 TTC25 617095 ODA Static  76 
 MNS1 610766 ODA Normal Milder resp. phenotype 90 
Pre- DNAAF1 613190 ODA + IDA Static  79,80 
assembly DNAAF2 612517 ODA + IDA Static  81 
Factor DNAAF3 614566 ODA + IDA Static  82 
 DNAAF4 608706 ODA + IDA Static  83 
 DNAAF5 614864 ODA + IDA Static  84 
 LRRC6 614930 ODA + IDA Static  85 
 ZMYND10 607070 ODA + IDA Static  86,87 
 SPAG1 603395 ODA + IDA Static  88 
 C21ORF59 615494 ODA + IDA Static  89 
 PIH1D3 300933 ODA + IDA Static  59,60 
 CFAP300 618058 ODA + IDA Static  155 
Axonemal CCDC39 613798 MTD + IDA 
Reduced bend and 
amplitude 
More severe resp. pheno 
and poorer nutrition8,9 
91 
ruler CCDC40 613798 MTD + IDA 
Reduced bend and 
amplitude 
More severe resp. pheno 
and poorer nutrition8,9 
92,15
6 
N-DRC CCDC164 615288 MTD /normal 
Hyperfrequent/ 
dyskinetic/ normal 
Situs solitus 
93 
 
 
 CCDC65 611088 MTD /normal 
Hyperfrequent/ 
dyskinetic/ normal 
Situs solitus 
89,15
7 
 GAS8 605178 MTD /normal 
Hyperfrequent/ 
dyskinetic/ normal 
Situs solitus 
40,88
45,94 
Radial 
spoke 
RSPH1 609314 CC/ normal Circling$$$ 
Normal NO + milder resp. 
phenotype. Situs solitus 
95 
Subunit RSPH4A 612647 CC/ normal Circling$$$ 
Situs solitus, increased 
chance of OM132149 
158 
 RSPH9 612648 CC/ normal Circling$$$ 
Situs solitus; increased 
chance of OM149 
96 
 RSPH3 615876 CC/ normal Circling$$$ 
Situs solitus; increased 
chance of OM149 
97 
 DNAJB13 610263 CC/ normal Circling$$$  98 
Central 
pair 
HYDIN 610812 
C2b projection/ 
normal 
Dyskinetic$$$ Situs solitus 100 
Subunit STK36 607652 normal Dyskinetic$$$  46 
Other CCNO 607752 
Mislocalisation of 
basal body  + 
reduction of cilia 
RGMC 
More severe + 
Hydrocepahlus 
102 
 MCIDAS* 614086 
Mislocalisation of 
basal body + 
reduction of cilia  
ODA+IDA 
RGMC 
More severe + 
Hydrocepahlus 
101 
 CCDC11 614759 normal normal Normal/mild? 103 
 ENKUR 611025 N.A. normal Normal/mild? 104 
 GAS2L2 611398 normal 
Normal/ 
disorientation 
 44 
 LRRC56* 618227 normal Dyskinetic  78 
TEM: transmission electron microscopy; HSVMA: high-speed video microscopy analysis; RGMC: reduced generation of 
multiple motile cilia; ODA: outer dynein arm; IDA: Inner dynein arm; N-DRC: nexin-dynein regulatory complex NO: nasal 
nitric oxide; MTD: Microtubular disorganization; N.A.: not applicable; OM: otitis media 
* Not always detectable by immunofluorescence using targeted antibodies  
$ Ultrastructural defects can be identified by electron tomography 
$$Refers only to the His154Pro missense mutation  
$$$When viewed from above. Sometimes can appear dyskinetic or more normal 
 
 
  
 Figure legends 
Figure 1: Over 40 genes have been reported to cause PCD. This figure summarises the genes which 
can be associated with PCD by effecting ciliary proteins, transport of those proteins, or docking of 
structures. ODA= outer dynein arm; CP= central pair; N-DCR=nexin-dynein regulatory complex. 
Figure 2: Transmission electron microscopy images of: A) Outer dynein arm defects B) Inner and 
outer dynein arm defects C) Microtubular disorganisation and inner dynein arm defect D) Normal 
ultrastructure E) Central complex defect showing separation of the central pair and translocation of 
an outer microtubular doublet.  
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